GALAPAGOS NV (GXE.DE) Fundamental Analysis & Valuation

FRA:GXE • BE0003818359

Current stock price

24.38 EUR
-0.32 (-1.3%)
Last:

This GXE.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. GXE.DE Profitability Analysis

1.1 Basic Checks

  • GXE had positive earnings in the past year.
  • In the past year GXE has reported a negative cash flow from operations.
  • The reported net income has been mixed in the past 5 years: GXE reported negative net income in multiple years.
  • GXE had a negative operating cash flow in each of the past 5 years.
GXE.DE Yearly Net Income VS EBIT VS OCF VS FCFGXE.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 9.42%, GXE belongs to the top of the industry, outperforming 86.42% of the companies in the same industry.
  • GXE has a Return On Equity of 9.92%. This is amongst the best in the industry. GXE outperforms 81.48% of its industry peers.
  • With an excellent Return On Invested Capital value of 11.32%, GXE belongs to the best of the industry, outperforming 87.65% of the companies in the same industry.
Industry RankSector Rank
ROA 9.42%
ROE 9.92%
ROIC 11.32%
ROA(3y)5.36%
ROA(5y)1.9%
ROE(3y)6.68%
ROE(5y)1.5%
ROIC(3y)N/A
ROIC(5y)N/A
GXE.DE Yearly ROA, ROE, ROICGXE.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 -10

1.3 Margins

  • The Profit Margin of GXE (28.85%) is better than 85.19% of its industry peers.
  • Looking at the Operating Margin, with a value of 47.04%, GXE belongs to the top of the industry, outperforming 95.06% of the companies in the same industry.
  • GXE has a better Gross Margin (97.33%) than 95.06% of its industry peers.
  • In the last couple of years the Gross Margin of GXE has declined.
Industry RankSector Rank
OM 47.04%
PM (TTM) 28.85%
GM 97.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.64%
GM growth 5YN/A
GXE.DE Yearly Profit, Operating, Gross MarginsGXE.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. GXE.DE Health Analysis

2.1 Basic Checks

  • GXE has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for GXE remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, GXE has more shares outstanding
  • GXE has a better debt/assets ratio than last year.
GXE.DE Yearly Shares OutstandingGXE.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
GXE.DE Yearly Total Debt VS Total AssetsGXE.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 7.67 indicates that GXE is not in any danger for bankruptcy at the moment.
  • GXE has a Altman-Z score of 7.67. This is amongst the best in the industry. GXE outperforms 83.95% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that GXE is not too dependend on debt financing.
  • GXE's Debt to Equity ratio of 0.00 is amongst the best of the industry. GXE outperforms 92.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.67
ROIC/WACC1.39
WACC8.12%
GXE.DE Yearly LT Debt VS Equity VS FCFGXE.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

2.3 Liquidity

  • GXE has a Current Ratio of 20.15. This indicates that GXE is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 20.15, GXE belongs to the best of the industry, outperforming 97.53% of the companies in the same industry.
  • A Quick Ratio of 20.00 indicates that GXE has no problem at all paying its short term obligations.
  • GXE has a Quick ratio of 20.00. This is amongst the best in the industry. GXE outperforms 97.53% of its industry peers.
Industry RankSector Rank
Current Ratio 20.15
Quick Ratio 20
GXE.DE Yearly Current Assets VS Current LiabilitesGXE.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. GXE.DE Growth Analysis

3.1 Past

  • GXE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 334.82%, which is quite impressive.
  • GXE shows a strong growth in Revenue. In the last year, the Revenue has grown by 280.53%.
  • GXE shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.97% yearly.
EPS 1Y (TTM)334.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3023.68%
Revenue 1Y (TTM)280.53%
Revenue growth 3Y58.87%
Revenue growth 5Y15.97%
Sales Q2Q%1093.22%

3.2 Future

  • Based on estimates for the next years, GXE will show a very negative growth in Earnings Per Share. The EPS will decrease by -25.26% on average per year.
  • GXE is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -30.71% yearly.
EPS Next Y-141.18%
EPS Next 2Y-67.16%
EPS Next 3Y-45.56%
EPS Next 5Y-25.26%
Revenue Next Year1%
Revenue Next 2Y-2.91%
Revenue Next 3Y-9.92%
Revenue Next 5Y-30.71%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GXE.DE Yearly Revenue VS EstimatesGXE.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
GXE.DE Yearly EPS VS EstimatesGXE.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

2

4. GXE.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 5.01, the valuation of GXE can be described as very cheap.
  • Based on the Price/Earnings ratio, GXE is valued cheaply inside the industry as 96.30% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 27.42. GXE is valued rather cheaply when compared to this.
  • GXE is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 5.01
Fwd PE N/A
GXE.DE Price Earnings VS Forward Price EarningsGXE.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -7.38
GXE.DE Per share dataGXE.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • GXE's earnings are expected to decrease with -45.56% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-67.16%
EPS Next 3Y-45.56%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GXE.DE Dividend Analysis

5.1 Amount

  • No dividends for GXE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GXE.DE Fundamentals: All Metrics, Ratios and Statistics

GALAPAGOS NV

FRA:GXE (4/24/2026, 7:00:00 PM)

24.38

-0.32 (-1.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)05-06
Inst Owners25.28%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap1.61B
Revenue(TTM)1.11B
Net Income(TTM)320.88M
Analysts52.22
Price Target29.82 (22.31%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9817.73%
Min EPS beat(2)-19965.4%
Max EPS beat(2)329.9%
EPS beat(4)1
Avg EPS beat(4)-5598.11%
Min EPS beat(4)-19965.4%
Max EPS beat(4)329.9%
EPS beat(8)4
Avg EPS beat(8)-2634.25%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)487.56%
Min Revenue beat(2)-2.86%
Max Revenue beat(2)977.98%
Revenue beat(4)2
Avg Revenue beat(4)242.3%
Min Revenue beat(4)-10.27%
Max Revenue beat(4)977.98%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.89%
PT rev (3m)-1.29%
EPS NQ rev (1m)-32.89%
EPS NQ rev (3m)-32.89%
EPS NY rev (1m)18.36%
EPS NY rev (3m)-11.68%
Revenue NQ rev (1m)-0.81%
Revenue NQ rev (3m)-0.81%
Revenue NY rev (1m)1.04%
Revenue NY rev (3m)0.54%
Valuation
Industry RankSector Rank
PE 5.01
Fwd PE N/A
P/S 1.44
P/FCF N/A
P/OCF N/A
P/B 0.5
P/tB 0.5
EV/EBITDA -7.38
EPS(TTM)4.87
EY19.98%
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)-4.12
FCFYN/A
OCF(TTM)-3.91
OCFYN/A
SpS16.88
BVpS49.1
TBVpS49.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number73.3514 (200.87%)
Profitability
Industry RankSector Rank
ROA 9.42%
ROE 9.92%
ROCE 16.08%
ROIC 11.32%
ROICexc 144.09%
ROICexgc 144.57%
OM 47.04%
PM (TTM) 28.85%
GM 97.33%
FCFM N/A
ROA(3y)5.36%
ROA(5y)1.9%
ROE(3y)6.68%
ROE(5y)1.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.64%
GM growth 5YN/A
F-Score6
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0.01
Cap/Depr 24.8%
Cap/Sales 1.25%
Interest Coverage 1127.48
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.15
Quick Ratio 20
Altman-Z 7.67
F-Score6
WACC8.12%
ROIC/WACC1.39
Cap/Depr(3y)83.14%
Cap/Depr(5y)94.58%
Cap/Sales(3y)13.02%
Cap/Sales(5y)12.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)334.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3023.68%
EPS Next Y-141.18%
EPS Next 2Y-67.16%
EPS Next 3Y-45.56%
EPS Next 5Y-25.26%
Revenue 1Y (TTM)280.53%
Revenue growth 3Y58.87%
Revenue growth 5Y15.97%
Sales Q2Q%1093.22%
Revenue Next Year1%
Revenue Next 2Y-2.91%
Revenue Next 3Y-9.92%
Revenue Next 5Y-30.71%
EBIT growth 1Y377.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.82%
EBIT Next 3Y8.25%
EBIT Next 5Y15.02%
FCF growth 1Y32.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.55%
OCF growth 3YN/A
OCF growth 5YN/A

GALAPAGOS NV / GXE.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of GALAPAGOS NV (GXE.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to GXE.DE.


What is the valuation status for GXE stock?

ChartMill assigns a valuation rating of 2 / 10 to GALAPAGOS NV (GXE.DE). This can be considered as Overvalued.


How profitable is GALAPAGOS NV (GXE.DE) stock?

GALAPAGOS NV (GXE.DE) has a profitability rating of 5 / 10.


What are the PE and PB ratios of GALAPAGOS NV (GXE.DE) stock?

The Price/Earnings (PE) ratio for GALAPAGOS NV (GXE.DE) is 5.01 and the Price/Book (PB) ratio is 0.5.